Metastatic Thymic Carcinoma & B3-thymoma.
Conditions
Brief summary
Progression free survival (PFS) rate at 5 months, defined as the percentage of patients with B3-Thymoma and TC without disease progression at 5 months after starting the treatment combination.
Detailed description
Response rate (RR) with the treatment combination, Maximum tumor shrinkage with the treatment combination, Disease control rate (DCR) with the treatment combination, Duration of response (DoR) with the treatment combination, Overall survival (OS), Safety and toxicity profile of the combination according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v.5.0).
Interventions
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
DRUGLenvatinib
Sponsors
Medica Scientia Innovation Research S.L.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS) rate at 5 months, defined as the percentage of patients with B3-Thymoma and TC without disease progression at 5 months after starting the treatment combination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate (RR) with the treatment combination, Maximum tumor shrinkage with the treatment combination, Disease control rate (DCR) with the treatment combination, Duration of response (DoR) with the treatment combination, Overall survival (OS), Safety and toxicity profile of the combination according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v.5.0). | — |
Countries
France, Italy, Spain
Outcome results
None listed